Evidence map›Paper›PMID 31727780›Full record

ArticleThe Journal of experimental medicine2020

B cell tolerance and antibody production to the celiac disease autoantigen transglutaminase 2.

M Fleur du Pré, Jana Blazevski, Alisa E Dewan, Jorunn Stamnaes, Chakravarthi Kanduri, Geir Kjetil Sandve, Marie K Johannesen, Christian B Lindstad, Kathrin Hnida, Lars Fugger and 3 more

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of experimental medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 53 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. T-betNature communications · 2024
    Article
  8. Article
  9. Article
  10. A Mouse Model of Celiac Disease.Current protocols · 2022
    Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Autoantibodies in neurological disease.Nature reviews. Immunology · 2021
    Review
  18. Review
  19. Article
  20. Current and emerging therapies for coeliac disease.Nature reviews. Gastroenterology & hepatology · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

M Fleur du PréK.G. Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway.
Jana BlazevskiDepartment of Immunology, University of Oslo, Oslo, Norway.
Alisa E DewanK.G. Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway.
Jorunn StamnaesK.G. Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway.
Chakravarthi KanduriK.G. Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway.
Geir Kjetil SandveK.G. Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway.
Marie K JohannesenK.G. Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway.
Christian B LindstadK.G. Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway.
Kathrin HnidaDepartment of Immunology, University of Oslo, Oslo, Norway.
Lars FuggerOxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology and Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.
Gerry MelinoDepartment of Experimental Medicine, TOR, University of Rome "Tor Vergata", Rome, Italy.
Shuo-Wang QiaoK.G. Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway.
Ludvig M SollidK.G. Jebsen Coeliac Disease Research Centre, University of Oslo, Oslo, Norway.
University of Oslo · NOOslo University Hospital · NOJohn Radcliffe Hospital · GBUniversity of Rome Tor Vergata · IT

Funding

Medical Research Council MC_U132670600Medical Research Council MC_UU_00025/2
6 · The paper itself

Abstract

Autoantibodies to transglutaminase 2 (TG2) are hallmarks of celiac disease. To address B cell tolerance and autoantibody formation to TG2, we generated immunoglobulin knock-in (Ig KI) mice that express a prototypical celiac patient-derived anti-TG2 B cell receptor equally reactive to human and mouse TG2. We studied B cell development in the presence/absence of autoantigen by crossing the Ig KI mice to Tgm2-/- mice. Autoreactive B cells in Tgm2+/+ mice were indistinguishable from their naive counterparts in Tgm2-/- mice with no signs of clonal deletion, receptor editing, or B cell anergy. The autoreactive B cells appeared ignorant to their antigen, and they produced autoantibodies when provided T cell help. The findings lend credence to a model of celiac disease where gluten-reactive T cells provide help to autoreactive TG2-specific B cells by involvement of gluten-TG2 complexes, and they outline a general mechanism of autoimmunity with autoantibodies being produced by ignorant B cells on provision of T cell help.

Indexed as

AnimalsAntibody FormationAutoantibodiesAutoantigensAutoimmunityB-LymphocytesCD4-Positive T-LymphocytesCeliac DiseaseGene Knock-In TechniquesGlutensGTP-Binding ProteinsHEK293 CellsHumansImmune ToleranceLymphocyte ActivationMiceAutoantibodiesAutoantigensGlutensGTP-Binding ProteinsProtein Glutamine gamma Glutamyltransferase 2Receptors, Antigen, B-CellTGM2 protein, humanTransglutaminases

Identifiers

PMID31727780
PMCPMC7041703
OpenAlexW2986539960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.